To assess the efficacy and safety of istradefylline as an adjunct to levodopa in patients with Parkinson's Disease (PD).
In this study, we searched the Cochrane Library, MEDLINE, Embase, China Academic Journal Full-text Database (CNKI), China Biomedical Literature Database (CBM), Chinese Scientific Journals Database (VIP), and Wanfang Database. The quality of included studies was strictly evaluated. Data analyses were performed by the Cochrane Collaboration's RevMan5.0 software.
Five randomized controlled trials (RCTs) were included. The result showed a significant reduction of the awake time per day spent in the OFF state and improvement of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III in the ON state when receiving istradefylline compared with patients receiving placebo. There was no significant difference between the istradefylline 20 mg and the istradefylline 40 mg groups in the UPDRS Part III in the ON state (WMD=1.27, 95% CI [−0.40, 2.95]). The results showed significant differences in dyskinesia (RR=1.63, 95% CI [1.16, 2.29]) compared to istradefylline 40 mg with placebo. There was no significant statistical difference with regard to other adverse events.
The present study showed that istradefylline is safe and effective as an adjunct to levodopa in patients with PD. Future large-scale, higher-quality, long-treatment, and placebo-controlled trials are needed.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Adenosine A(2A) receptors in Parkinson's disease treatment.Purinergic Signal. 2008; 4: 305-312
- Science, medicine, and the future: Parkinson's disease.BMJ. 1999; 318: 311-314
- Treatment of Parkinson's disease.N Engl J Med. 1993; 329: 1021-1027
- Treatment of Parkinson's disease: levodopa as the first choice.J Neurol. 2002; 249: II19-II24
- Pharmacokinetics of levodopa.Clin Neuropharmacol. 1984; 7: 35-49
- Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I.Ann Neurol. 1988; 249: 366-371
- Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.Mov Disord. 2001; 16: 448-458
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.Neurology. 2007; 68: 384-386
- A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.Neurology. 2003; 61: S32-S38
- Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain.Brain Res. 2002; 953: 119-125
- Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.Psychopharmacology (Berl). 1999; 147: 90-95
- Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.Expert Opin Investig Drugs. 2005; 14: 729-738
- Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.Neurology. 2003; 61: S97-S100
- Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.J Neurochem. 2003; 84: 1398-1410
- Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.Exp Neurol. 2000; 162: 321-327
- What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study.Neurology. 1992; 42: 1142-1146
- Parkinsonism: onset, progression and mortality.Neurology. 1967; 17: 427-442
- Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).Ann Neurol. 2008; 63: 295-302
- Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.Mov Disord. 2010; 25: 1437-1443
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.Parkinsonism Relat Disord. 2012; 18: 178-184
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.Mov Disord. 2008; 23: 2177-2185
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.Neurology. 2008; 70: 2233-2240
Published online: October 22, 2012
Accepted: August 30, 2012
Received in revised form: August 27, 2012
Received: May 31, 2012
© 2012 Elsevier B.V. Published by Elsevier Inc. All rights reserved.